100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
864070-37-1O-Desethyl Dapagliflozin
● In Stock
| Catalogue No.: | VL1650009 |
|---|---|
| CAS No.: | 864070-37-1 |
| Mol. Formula: | C19H21ClO6 |
| Mol. Weight: | 380.82 g/mol |
Order Online
Additional information on CAS 864070-37-1
Parent drug
DapagliflozinIUPAC Name
(1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-hydroxyphenyl)methyl]phenyl]-D-glucitolPharmacopoeial Synonyms
Dapagliflozin FP Impurity AOther Synonyms
N/ASmiles
ClC(C=C1)=C(CC2=CC=C(O)C=C2)C=C1[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3InChI
InChI=1S/C19H21ClO6/c20-14-6-3-11(8-12(14)7-10-1-4-13(22)5-2-10)19-18(25)17(24)16(23)15(9-21)26-19/h1-6,8,15-19,21-25H,7,9H2/t15-,16-,17+,18-,19+/m1/s1Description
O-Desethyl Dapagliflozin, also designated Dapagliflozin FP-Impurity A, is a chlorinated desethyl analog of the SGLT2 inhibitor dapagliflozin, corresponding to CAS 864070-37-1. With molecular formula C19H21ClO6 and molecular weight 380.82 g/mol, it differs from the parent drug by loss of the ethyl substituent on the phenoxy oxygen, consistent with a synthetic intermediate, process-related byproduct, or hydrolytic/dealkylative degradant. Its characterization typically relies on LC-MS/MS, high-resolution LC-MS, and orthogonal LC-UV methods, with NMR used for structural confirmation. As a related impurity, it is generally evaluated within impurity control frameworks rather than as a nitrosamine or genotoxic alert species.References
Haider, Kashif, et al. “Synthetic Strategy and SAR Studies of C-Glucoside Heteroaryls as SGLT2 Inhibitor: A Review.†European Journal of Medicinal Chemistry, vol. 184, Dec. 2019, p. 111773, https://doi.org/10.1016/j.ejmech.2019.111773.?Docherty, Kieran F., et al. “Effects of Dapagliflozin in DAPA-HF according to Background Heart Failure Therapy.†European Heart Journal, vol. 41, no. 25, Mar. 2020, pp. 2379–92, https://doi.org/10.1093/eurheartj/ehaa183.Request a Quote
"*" indicates required fields
Other products related to Dapagliflozin impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
